Holen Sie sich die Stockscreener-App
96.79
1.80%
-1.77
Schlusskurs vom Vortag:
$98.56
Offen:
$98.18
24-Stunden-Volumen:
2.16M
Relative Volume:
0.65
Marktkapitalisierung:
$21.14B
Einnahmen:
$819.56M
Nettoeinkommen (Verlust:
$-1.18B
KGV:
-16.85
EPS:
-5.7434
Netto-Cashflow:
$-951.64M
1W Leistung:
-4.87%
1M Leistung:
-22.75%
6M Leistung:
-36.90%
1J Leistung:
-40.02%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$96.54
$101.82
52-Wochen-Spanne:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
96.79 | 21.14B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-09-24 | Fortgesetzt | Goldman | Buy |
| 2026-07-21 | Eingeleitet | BMO Capital Markets | Outperform |
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2026-03-30 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-23 | Eingeleitet | Roth Capital | Buy |
| 2025-12-19 | Fortgesetzt | Truist | Buy |
| 2025-12-04 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Wolfe Research Downgrades Insmed to Peer Perform From Outperform - Moomoo
Truist previews biotech earnings with focus on Insmed, BridgeBio By Investing.com - Investing.com Canada
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
BofA cuts Insmed stock price target on valuation concerns By Investing.com - Investing.com India
US High Growth Tech Stocks Spotlight Featuring 3 Top Picks - Simply Wall Street
UBS reiterates Insmed stock rating on Brinsupri sales outlook - Investing.com
Does Insmed (INSM) CFO Exit With Reaffirmed Guidance Clarify Or Complicate Its Growth Narrative? - Yahoo Finance
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View - Zacks Investment Research
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View - TradingView
Bonstein to step down as Insmed chief financial officer - ROI-NJ
$100 Invested In Insmed 5 Years Ago Would Be Worth This Much Today - Benzinga
Insmed Announces CFO Transition - Insmed Incorporated Investor Relations
Insmed stock falls as CFO Sara Bonstein to step down - Investing.com
Why is Insmed stock sliding today? By Investing.com - Investing.com India
Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed - Benzinga
Insmed stock falls as CFO Sara Bonstein to step down - Yahoo Finance
Insmed drops as investors weigh CFO departure despite reaffirmed 2026 outlook - Quiver Quantitative
Insmed Incorporated Announces Sara Bonstein Steps Down as Chief Financial Officer, Effective October 30, 2026 - marketscreener.com
Insmed Incorporated Reaffirms Earnings Guidance for the Full-Year 2026 - marketscreener.com
Insmed Q2 2026 Earnings Call Transcript - Benzinga
Insmed CFO Sara Bonstein to step down, reaffirms guidance - TradingView
Insmed CFO Sara Bonstein to step down on October 30 By Investing.com - Investing.com Canada
Insmed CFO Sara Bonstein to step down Oct 30; c... - pluang.com
Insmed CFO Sara Bonstein to Separate, Search Underway for Successor - TradingView
Insmed (INSM) Announces CFO Transition - TradingView
INSM5182680 Bond Profile: Coupon and Redemption - TradingView
Insmed Incorporated (INSM) stock price, news, quote and history - Yahoo Finance UK
Insmed IncorporatedCommon Stock (Nasdaq:INSM) Stock Quote - FinancialContent
Insmed Incorporated (INSM) stock price, news, quote and history - Yahoo Finance UK
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback - Zacks Investment Research
Total liabilities & shareholders' equities of Insmed Incorporated – HAN:IM8N - TradingView
Goldman Sachs initiates Insmed stock coverage with buy rating, $188 target - Investing.com
Insmed Incorporated (INSM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insmed Incorporated (INSM) stock price, news, quote and history - Yahoo Finance Singapore
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - Zacks Investment Research
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - Yahoo Finance
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - TradingView
Insmed stock price target maintained at $195 by Mizuho on FDA review - Investing.com Canada
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Did FDA Priority Review of ARIKAYCE ENCORE Data Just Shift Insmed's (INSM) Investment Narrative? - Yahoo Finance
FDA Grants Priority Review To Insmed's SNDA For Arikayce For Treatment Of Mac Lung Disease With PDUFA Target Action Date Set For January 28, 2027 - TradingView
Insmed receives FDA priority review for ARIKAYCE - grafa.com
FDA grants Priority Review to Insmed's ARIKAYCE for full approval in treating MAC lung disease - Pluang
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 - Insmed Incorporated Investor Relations
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 - PR Newswire
Insmed Incorporated (INSM) Gets FDA Priority Review; PDUFA Jan 28, 2027 - TradingView
Insmed stock slips after strong earnings surprise and rich valuation debate - AD HOC NEWS
The Fund Exited Insmed (INSM) After the Investment Thesis Played Out - Yahoo Finance
Insmed Expands Community Impact During Fifth Annual Global Day of Good - PR Newswire
Insmed Expands Community Impact During Fifth Annual Global Day of Good - Yahoo Finance
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Insmed Inc-Aktie (INSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Brennan David R | Director |
Sep 09 '26 |
Proposed Sale |
123.99 |
25,000 |
3,099,729 |
0 |
| SHAROKY MELVIN MD | Director |
Aug 17 '26 |
Sale |
127.53 |
5,000 |
637,650 |
0 |
| MELVIN SHAROKY | Director |
Aug 17 '26 |
Proposed Sale |
127.53 |
5,000 |
637,637 |
0 |
| Roger Adsett | Officer |
Aug 10 '26 |
Proposed Sale |
133.26 |
239,850 |
31,963,198 |
0 |
| Adsett Roger | Chief Operating Officer |
Aug 10 '26 |
Option Exercise |
20.45 |
239,850 |
4,905,570 |
338,594 |
| Adsett Roger | Chief Operating Officer |
Aug 10 '26 |
Sale |
133.27 |
239,850 |
31,964,810 |
98,744 |
| Martina Flammer | Officer |
Aug 06 '26 |
Proposed Sale |
128.61 |
27,173 |
3,494,755 |
0 |
| Flammer Martina M.D. | Chief Medical Officer |
Aug 06 '26 |
Option Exercise |
21.20 |
27,173 |
576,126 |
87,659 |
| Flammer Martina M.D. | Chief Medical Officer |
Aug 06 '26 |
Sale |
128.61 |
27,173 |
3,494,838 |
60,486 |
| Lewis William | Chair and CEO |
Jul 23 '26 |
Sale |
106.06 |
10,700 |
1,134,890 |
259,058 |
2.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):